

Spiriva[®] HandiHaler[®] (tiotropium) – First-time generic

- On August 16, 2023, [Lupin launched](#) an [AB-rated](#) generic version of Boehringer Ingelheim's [Spiriva HandiHaler \(tiotropium\)](#) inhalation capsules.
 - Lupin was granted 180-days of generic exclusivity.
- Spiriva HandiHaler is approved for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Spiriva HandiHaler is indicated to reduce exacerbations in COPD patients.
- Tiotropium is also available as brand [Spiriva Respimat[®]](#) inhalation solution.
 - Spiriva Respimat carries the same indication as Spiriva HandiHaler and is also approved for long-term, once-daily, maintenance treatment of asthma in patients 6 years of age and older.
- According to IQVIA, Spiriva HandiHaler annual sales for the 12-month period ending in March 2023 were \$1.3 billion.